Drugs / IFNα
last change Jun 2025 re-read 2 minutes ago

IFNα

Developed for
ovarian cancer
Investigated by
AIM ImmunoTech Inc. · National Cancer Institute (NCI) · Roswell Park Cancer Institute · University of Pittsburgh

Trials 1 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02432378 Sep 2015 → Jun 2025 ovarian cancer Roswell Park Cancer Institute Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IFNα “Patients in cohorts 2, 3, and 4 also received intraperitoneal IFNα at 2, 6, and 18 million units (MU), respectively.” PMID 35046055 May 2022
Route Other “Patients in cohorts 2, 3, and 4 also received intraperitoneal IFNα at 2, 6, and 18 million units (MU), respectively.” PMID 35046055 May 2022